Skip to main content

Table 6 Baseline clinicopathological characteristics of the three groups in the internal validation cohort

From: A novel preoperative inflammation score system established for postoperative prognosis predicting of intrahepatic cholangiocarcinoma

Variables

level

Low IFS score

Median IFS score

High IFS score

P value

  

N = 42

 N = 110

 N = 23

 

Age, year (mean ± SD)

 

58.12 ± 9.78

56.56 ± 10.68

58.87 ± 10.80

0.521

Sex (%)

female

14 (33.3)

34 (30.9)

6 (26.1)

0.833

 

male

28 (66.7)

76 (69.1)

17 (73.9)

 

Hepatolithiasis (%)

no

42 (100.0)

106 (96.4)

22 (95.7)

0.436

 

yes

0 (0.0)

4 (3.6)

1 (4.3)

 

Diabetes (%)

no

38 (90.5)

101 (91.8)

22 (95.7)

0.758

 

yes

4 (9.5)

9 (8.2)

1 (4.3)

 

HBsAg (+) (%)

no

22 (52.4)

67 (60.9)

15 (65.2)

0.526

 

yes

20 (47.6)

43 (39.1)

8 (34.8)

 

Anti-HCV (%)

no

42 (100.0)

110 (100.0)

22 (95.7)

0.036

 

yes

0 (0.0)

0 (0.0)

1 (4.3)

 

Child-Pugh grade (%)

A

37 (88.1)

104 (94.5)

17 (73.9)

0.027

 

B

2 (4.8)

4 (3.6)

4 (17.4)

 

TBIL, mg/dL*

 

12.45 [10.03, 16.17]

11.90 [9.83, 14.35]

10.30 [8.85, 12.25]

0.153

ALT, IU/L*

 

18.50 [14.00, 25.90]

21.90 [14.00, 31.08]

28.00 [15.75, 46.00]

0.151

AST, IU/L*

 

22.15 [17.00, 27.88]

22.95 [17.25, 31.75]

31.80 [23.05, 42.00]

0.012

GGT, IU/L*

 

49.00 [28.25, 86.25]

73.50 [38.25, 154.75]

92.00 [55.00, 199.00]

0.079

HgB, g/L (mean ± SD)

 

136.05 ± 15.16

134.75 ± 13.86

124.65 ± 18.64

0.007

PT, second*

 

11.55 (1.17)

11.65 (0.90)

12.22 (1.19)

0.027

ALB, g/L (mean ± SD)

 

42.69 ± 5.27

42.36 ± 3.37

40.00 ± 3.78

0.021

PLT, ×109/L*

 

162.00 [133.50, 199.00]

186.50 [146.25, 242.50]

185.00 [136.50, 223.00]

0.054

WBC, ×109/L*

 

5.98 [4.66, 6.82]

6.08 [5.03, 7.46]

6.13 [5.04, 8.27]

0.428

AFP, µg/L*

 

3.50 [1.90, 6.05]

3.05 [2.12, 5.70]

6.60 [2.40, 21.00]

0.208

CEA, µg/L*

 

2.30 [1.40, 3.65]

2.90 [2.00, 6.10]

3.30 [1.55, 4.70]

0.024

CA199, IU/mL*

 

36.45 [18.35, 124.85]

69.75 [24.20, 670.12]

45.20 [16.65, 171.60]

0.104

Perioperative transfusion (%)

no

37 (88.1)

96 (87.3)

19 (82.6)

0.804

 

yes

5 (11.9)

14 (12.7)

4 (17.4)

 

Anatomic resection (%)

no

30 (71.4)

71 (64.5)

13 (56.5)

0.472

 

yes

12 (28.6)

39 (35.5)

10 (43.5)

 

Major resection (%)

no

30 (71.4)

74 (67.3)

18 (78.3)

0.559

 

yes

12 (28.6)

36 (32.7)

5 (21.7)

 

Cirrhosis (%)

no

31 (73.8)

89 (80.9)

15 (65.2)

0.223

 

yes

11 (26.2)

21 (19.1)

8 (34.8)

 

Tumor diameter, cm (mean ± SD)

 

5.55 ± 3.54

6.58 ± 3.60

8.02 ± 3.76

0.031

Multiple tumors (%)

no

34 (81.0)

70 (63.6)

18 (78.3)

0.073

 

yes

8 (19.0)

40 (36.4)

5 (21.7)

 

Satellite nodules (%)

no

27 (64.3)

58 (52.7)

16 (69.6)

0.203

 

yes

15 (35.7)

52 (47.3)

7 (30.4)

 

Tumor capsule (%)

no

40 (95.2)

100 (90.9)

21 (91.3)

0.747

 

complete

1 (2.4)

7 (6.4)

2 (8.7)

 
 

incomplete

1 (2.4)

3 (2.7)

0 (0.0)

 

Tumor differentiation (%)

low

3 (7.1)

9 (8.2)

3 (13.0)

0.466

 

median

37 (88.1)

96 (87.3)

17 (73.9)

 
 

high

2 (4.8)

5 (4.5)

3 (13.0)

 

Adjacent tissue invasion (%)

no

40 (95.2)

105 (95.5)

20 (87.0)

0.267

 

yes

2 (4.8)

5 (4.5)

3 (13.0)

 

MVI (%)

no

35 (83.3)

88 (80.0)

21 (91.3)

0.425

 

yes

7 (16.7)

22 (20.0)

2 (8.7)

 

LNM (%)

no

40 (95.2)

96 (87.3)

19 (82.6)

0.242

 

yes

2 (4.8)

14 (12.7)

4 (17.4)

 
  1. Abbreviations: HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; TBIL, total bilirubin; ALB, albumin; ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; PT, prothrombin time; PLT, platelet; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbonhydrateantigen19-9; MVI, microvascular invasion; LNM, lymph node metastasis
  2. * Quantitative variables shown with median and interquartile range (IQR)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us